Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...
Progenics Pharmaceuticals announced that it will hand over commercial duties on Relistor, a subcutaneous injection for opioid-induced constipation (OIC), to Salix, beginning in April. Financial terms ...
TARRYTOWN, N.Y., Oct 14, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth ...
RELISTOR(R) (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic ...
TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced it has extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to continue Wyeth’s ...
TARRYTOWN, N.Y. & RALEIGH, N.C.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that they have entered into an exclusive ...
Please provide your email address to receive an email when new articles are posted on . A single dose of Relistor injection produced rescue-free laxation in severely ill patients with opioid-induced ...
About 9-12 million Americans suffer from chronic pain annually, and most are prescribed opioid medications to treat and control their symptoms 1. While opioids can help relieve and manage chronic pain ...
Data from a Post-Hoc Analysis Supports the Use of Salix's RELISTOR for Patients with Opioid-Induced Constipation and Advanced Illness in the Emergency Department Setting LAVAL, QC, Dec. 22, 2021 ...
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced the Therapeutic Goods Administration (TGA) division of the Australian Government has approved the ...
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results